Technical Data
B2850-01F
Bromodeoxyuridine (BrdU)
Description:
The life cycle of a eukaryotic cell consists of various phases, two of which can easily be identified. Firstly, during mitosis (M-phase), in which the cell divides into two identical daughter cells, chromosome condensation and spindle formation are microscopically visible. Secondly, in S-phase the DNA of a cell is replicated, a process that can be detected using biochemical techniques. In between the M- and S-phase two gap phases occur: the G1-phase, the gap between mitosis and the start of DNA replication, and G2-phase, the gap between completion of DNA replication and the onset of mitosis. From G1-phase a cell can leave the cell cycle and enter G0, a ‘quiescent’ phase. Regulation of the cell cycle predominantly occurs at three major control points, which govern the transition from G0 to G1, from G1 to S and from G2 to M-phase.

Applications:
Suitable for use in Immunohistochemistry, Immunocytochemistry and Flow Cytometry. Other applications not tested.

Recommended Dilution:
Flow Cyotmetry: 1:50-1:100
Immunohistochemistry (Frozen and paraffin sections): Detection antibody with avidin-biotinylated horseradish peroxidase complex.

Optimal dilutions to be determined by researcher.

Hybridoma:
Hybridization of myeloma cells from SP2/0-Ag14 mice with spleen cells from Balb/c mice.

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage, store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
MabIgG14A9Affinity Purified
SizeStorageShippingSourceHost
100ug4°C (-20°C Glycerol)Blue IceMouse
Concentration:
~0.5mg/ml
Immunogen:
Bromodeoxyuridine (BrdU)-conjugate to BSA.
Purity:
Purified by Protein G affinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.2, 0.1% sodium azide, before the addition of 40% glycerol. No stabilizing proteins added.
Specificity:
Bromodeoxuridine, also when incorporated into nuclear DNA.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Schutte, B., et al., An improved method for the immunocytochemical detection of bromodeoxyuridine labeled nuclei using flow cytometry, Cytometry 8: 372-6 (1987). 2. Tinnemans, M.M., et al., Cytokinetic analysis of lung cancer by in vivo bromodeoxyuridine labelling, Br. J. Cancer 67: 1217-22 (1993). 3. van Engeland, M., et al., Plasma membrane alterations and cytoskeletal changes in apoptosis, Exp. Cell Res. 235: 421-430 (1997). 4. Schutte, B., et al., The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics, Exp. Cell Res. 236: 4-15 (1997).